Second-line therapy for advanced non-small-cell lung cancer

被引：2

作者：

Hann C.L. ^{[1
]}

Brahmer J.R. ^{[1
]}

机构：

[1] The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231-1000

来源：

Current Oncology Reports | 2006年 / 8卷 / 4期

关键词：

Bevacizumab; Docetaxel; Clin Oncol; Erlotinib; Pemetrexed;

D O I：

10.1007/s11912-006-0027-3

中图分类号：

学科分类号：

摘要：

Over the past three decades, progress has been made in the first-line treatment of advanced non-small-cell lung cancer (NSCLC). Current recommendations include combination chemotherapy with or without targeted therapy. Despite these advances, the majority of patients relapse after initial treatment. Many of these patients are eligible for second-line therapy, which has prompted significant clinical research in this area. In 1999, docetaxel became the first drug approved by the US Food and Drug Administration for the treatment of patients with advanced NSCLC in the second-line setting. In 2004, two additional agents, pemetrexed and erlotinib, also received approval, giving patients three options for second-line treatment. Many promising new drugs and drug combinations are currently under investigation. Copyright © 2006 by Current Science Inc.

引用

页码：243 / 247

页数：4

共 36 条

[1]

Graphs and Figures, (2005)

[2]

Spira A., Ettinger D.S., Multidisciplinary management of lung cancer, N Engl J Med, 350, pp. 379-392, (2004)

[3]

Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials, MMJ, 311, pp. 899-909, (1995)

[4]

Grilli R., Oxman A.D., Julian J.A., Chemotherapy for advanced non-small-cell lung cancer: How much benefit is enough?, J Clin Oncol, 11, pp. 1866-1872, (1993)

[5]

Souquet P.J., Chauvin F., Boissel J.P., Et al., Polychemotherapy in advanced non small cell lung cancer: A meta-analysis, Lancet, 342, pp. 19-21, (1993)

[6]

Pfister D.G., Johnson D.H., Azzoli C.G., Et al., American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003, J Clin Oncol, 22, pp. 330-353, (2004)

[7]

Sandler A.B., Gray R., Brahmer J., Et al., Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599, Proc ASCO, 23, (2005)

[8]

Huisman C., Smit E.F., Giaccone G., Postmus P.E., Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: A review, J Clin Oncol, 18, pp. 3722-3730, (2000)

[9]

Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer, J Clin Oncol, 15, pp. 2996-3018, (1997)

[10]

Fossella F.V., Lee J.S., Shin D.M., Et al., Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer, J Clin Oncol, 13, pp. 645-651, (1995)

← 1 2 3 4 →